New Data Set Up Padcev For Potential Expanded Use
Regulatory Discussions Planned
Positive top-line data from a second pivotal trial cohort are set to support regulatory filings for the ADC in patients whose cancer has progressed after immunotherapy but are ineligible for cisplatin.
